Albemarle expands South Haven API production site
Enables the company to advance its growing portfolio of custom products
Albemarle Corporation, a global developer, manufacturer and marketer of highly engineered speciality chemicals, has expanded and upgraded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Michigan. Production using the new expanded capacity commenced on 1 June 2012.
This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios.
In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status.
Albemarle Fine Chemistry Services specialises in enabling its customers to go to market in an efficient and fully compliant manner by providing comprehensive process development and validation capabilities followed by seamless transition into commercial-scale production. Albemarle uses the Quality by Design (QbD) approach to establish manufacturing processes and then speed validated commercial products to market.
